AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03790722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergometry L
Description: After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure.
Study NCT00498459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical promotion according to socio-ecological model Limitation of sedentary behaviour
Study NCT03585478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latiglutenase
Description: Latiglutenase administered orally (daily)
Study NCT03585478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally (daily)
Study NCT04067323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soya bean oil
Description: Participants will consume soya bean oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
Study NCT04067323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT oil
Description: Participants will consume MCT oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
Study NCT01847963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindhuvallathy mezhugu ( SVM)
Description: 500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
Study NCT01847963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalladaippu Kudineer (KK) -
Description: 130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
Study NCT04045327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline + Standard Treatment
Description: Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
Study NCT04045327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centhaquine + Standard Treatment
Description: Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
Study NCT03823183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Group-based cognitive training on iPads with commercially available video games (Lumosity) designed to enhance executive control, memory functions and processing speed. Difficulty will be automatically adjusted to the performance level of the participant. Participants will train for 40 min 2 days/wk over 3 months.
Study NCT03823183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Group-based fitness program (senior-friendly adaption of BodyAttack) that combines aerobic, strength and coordination training to a music soundtrack. Participants will train for 40 min, 2 days/wk over 3 months.
Study NCT03823183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive control
Description: Group-based cognitive control activity consisting of playing on iPads non-cognitively demanding video games during 40 min 2 days/wk over 3 months and exercises based on relaxation and stretching for 40 min, 2 days/wk over 3 months.
Study NCT03823183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive control
Description: Group-based cognitive control activity consisting of playing on iPads non-cognitively demanding video games during 40 min 2 days/wk over 3 months and exercises based on relaxation and stretching for 40 min, 2 days/wk over 3 months.
Study NCT03823183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical control
Description: Group-based exercises program (based on relaxation and stretching) for 40 min, 2 days/wk over 3 months.
Study NCT03823183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical control
Description: Group-based exercises program (based on relaxation and stretching) for 40 min, 2 days/wk over 3 months.
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 400 mg
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 800 mg
Description: Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 600 mg
Description: Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068 1200 mg
Description: Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400 mg
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 300 mg
Description: Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir 300 mg
Description: Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir 100 mg
Description: Tablets, Oral, 100 mg, Once daily, 96 weeks
Study NCT01384734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir 300 mg
Description: Capsules, Oral, 300 mg, Once daily, 96 weeks
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Before induction, midazolam 0.05mg/kg will be injected intravenously.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Before induction, midazolam 0.05mg/kg will be injected intravenously.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penehyclidine Hydrochloride Injection
Description: Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium Besilate
Description: Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium Besilate
Description: Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be injected continuously during maintenance of anesthesia.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil will be injected continuously during maintenance of anesthesia.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
Study NCT02202239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
Study NCT02987725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.
Study NCT02987725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: A 30-minute historical story read by a research clinician.
Study NCT00409539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 week duration.
Study NCT00409539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
Study NCT00409539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-986
Description: Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
Study NCT00689312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enfalyte
Description: Each patient will receive one 250 ml dose.
Study NCT00689312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pediatric Electrolyte
Description: Each patient will receive one 250 ml dose.
Study NCT00689312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pedialyte
Description: Each patient will receive one 250 ml dose.
Study NCT02763839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.
Study NCT02763839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
Study NCT02763839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet 25/100
Description: Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.
Study NCT03830359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T2769
Description: At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days
Study NCT00601497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterX 5000
Description: 20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
Study NCT00601497 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: InterX 5000
Description: 20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
Study NCT01104896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days
Study NCT01104896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
Study NCT02609958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: varlitinib tablets with:~1. starting dose: 300mg BID~2. target dose: 400mg BID~3. dose modification by investigator allowed between 200mg BID to 500mg BID
Study NCT00662207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrator
Description: A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
Study NCT00662207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal dilator
Description: A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
Study NCT03650491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR46
Description: FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
Study NCT02172963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual Stromal Cell therapy
Description: Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10\^6 cells/kg.
Study NCT01777074 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire, Vaccination book
Study NCT00957879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: Ergocalciferol 50000 international units by mouth weekly for 12 weeks
Study NCT00957879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Calcitriol 0.5 mcg by mouth daily for 12 weeks
Study NCT03195283 — intervention group
Intervention type: OTHER
Intervention: Meal service
Description: The type of meal service in the hospital (usual care)
Study NCT02023307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Loc Suture
Study NCT00374439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral
Description: Cognitive-behavioral approach
Study NCT00374439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Description: Interpersonal therapy approach
Study NCT03458312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family and Network Consultations
Description: Family and Network Consultation' (FNC) seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.~Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.
Study NCT05718466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT05718466 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated radiosurgery
Study NCT02972203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Primary Care
Description: • MPTC is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
Study NCT02972203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Intro. +resources +waitlist
Description: Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
Study NCT00905515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Maintain on cyclosporine at target trough level of 50-250 ng/mL.
Study NCT03259555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
Study NCT03259555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally daily for 3 weeks.
Study NCT00760955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
Study NCT00760955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
Study NCT00760955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-583
Description: TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
Study NCT00760955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
Study NCT02677168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cNEP
Description: continuous negative external pressure
Study NCT01332994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1 g intravenously at Week 16 and 18
Study NCT01332994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks for 12 weeks.
Study NCT01332994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
Study NCT02800863 — intervention group
Intervention type: DEVICE
Intervention: Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)
Description: Electrical stimulation of the DRG using the Axium™ Neurostimulator System
Study NCT02800863 — intervention group
Intervention type: DEVICE
Intervention: Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)
Description: Electrical Stimulation of the DRG using the Proclaim™ Neurostimulator System.
Study NCT02584179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biparametric MRI before biopsy
Description: All included men with suspicious lesions on bpMRI will have bpMRI targeted biopsies in addition to standard TRUS-bx.
Study NCT03583853 — intervention group
Intervention type: DEVICE
Intervention: real time PCR
Description: real time PCR will be used for determination of expression of autophagy genes
Study NCT02926989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte Glucos 50 mg/mL
Description: Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
Study NCT02926989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.45% saline in 5% dextrose
Description: Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
Study NCT01788917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Linseed oil
Description: Dietary supplement: 10 mL linseed oil per day
Study NCT01788917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Linseed oil
Description: Dietary supplement: 10 mL linseed oil per day
Study NCT02501252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trained midwives and nurses working in the community to provide skilled SBA services
Description: After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
Study NCT02501252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trained midwives and nurses working in the community to provide skilled SBA services
Description: After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
Study NCT00361881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-609
Description: Cream, dose 5 times daily during 5 days.
Study NCT00361881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir in ME-609 vehicle
Description: Dose 5 times daily for 5 days
Study NCT00905515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf (Tacrolimus)
Description: Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).